PTC Gross Profit from 2010 to 2024

PTCT Stock

USD 42.89 0.93 2.22%

PTC Therapeutics Gross Profit yearly trend continues to be comparatively stable with very little volatility. Gross Profit is likely to outpace its year average in 2024. Gross Profit is the profit PTC Therapeutics makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2004-12-31

Previous Quarter

168.3 M

Current Value

185.9 M

Quarterly Volatility

71.6 M

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check PTC Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among PTC Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 135.6 M, Total Revenue of 984.7 M or Research Development of 699.9 M, as well as many indicators such as Price To Sales Ratio of 2.09, Dividend Yield of 0.0 or Days Sales Outstanding of 51.74. PTC financial statements analysis is a perfect complement when working with PTC Therapeutics Valuation or Volatility modules.

Check out the analysis of PTC Therapeutics Correlation against competitors.

For more information on how to buy PTC Stock please use our How to Invest in PTC Therapeutics guide.

Latest PTC Therapeutics' Gross Profit Growth Pattern

Below is the plot of the Gross Profit of PTC Therapeutics over the last few years. Gross profit is a required income statement account that reflects total revenue of PTC Therapeutics minus its cost of goods sold. It is profit before PTC Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. PTC Therapeutics' Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in PTC Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 2.63 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

PTC Gross Profit Regression Statistics

	Arithmetic Mean	287,875,979
	Geometric Mean	164,996,294
	Coefficient Of Variation	109.50
	Mean Deviation	250,411,990
	Median	189,815,000
	Standard Deviation	315,228,746
	Sample Variance	99369.2T
	Range	972.8M
	R-Value	0.89
	Mean Square Error	22676.8T
	R-Squared	0.79
	Significance	0.00001
	Slope	62,574,817
	Total Sum of Squares	1391168.3T

PTC Gross Profit History

	2024	916 M
	2023	872.3 M
	2022	654.1 M
	2021	506.3 M
	2020	361.8 M
	2019	294.8 M
	2018	252.1 M

Other Fundumenentals of PTC Therapeutics

Gross Profit Margin

PTC Therapeutics Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Accounts Payable	Long Term Debt	Short Term Investments	Total Liab	Property Plant Equipment	Current Deferred Revenue	Net Debt	Retained Earnings	Net Receivables	Total Current Assets	Short Term Debt	Common Stock	Net Tangible Assets	Capital Surpluse	Long Term Debt Total	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		-0.24	0.66	0.65	0.67	0.92	0.78	0.27	0.48	-0.87	0.86	0.94	0.51	0.89	-0.85	0.94	0.81	0.24	0.69	0.84	0.93
Total Stockholder Equity	-0.24		0.0	-0.79	0.23	-0.6	-0.57	-0.01	-0.84	0.65	-0.63	-0.35	-0.64	-0.08	0.61	-0.29	-0.7	-0.46	-0.26	-0.08	-0.52
Accounts Payable	0.66	0.0		0.14	0.49	0.54	0.6	0.4	-0.01	-0.56	0.59	0.52	0.21	0.74	-0.6	0.69	0.45	0.2	0.03	0.43	0.62
Long Term Debt	0.65	-0.79	0.14		0.14	0.85	0.65	-0.09	0.95	-0.88	0.84	0.78	0.81	0.49	-0.76	0.61	0.91	0.41	0.7	0.5	0.76
Short Term Investments	0.67	0.23	0.49	0.14		0.46	0.42	0.37	0.03	-0.35	0.27	0.68	0.24	0.57	-0.25	0.58	0.26	0.38	0.46	0.86	0.57
Total Liab	0.92	-0.6	0.54	0.85	0.46		0.87	0.22	0.74	-0.98	0.96	0.91	0.68	0.76	-0.95	0.88	0.95	0.37	0.67	0.72	0.97
Property Plant Equipment	0.78	-0.57	0.6	0.65	0.42	0.87		0.63	0.5	-0.86	0.85	0.71	0.73	0.67	-0.87	0.77	0.76	0.45	0.4	0.51	0.88
Current Deferred Revenue	0.27	-0.01	0.4	-0.09	0.37	0.22	0.63		-0.24	-0.16	0.17	0.1	0.3	0.23	-0.26	0.25	-0.01	0.27	-0.07	0.11	0.28
Net Debt	0.48	-0.84	-0.01	0.95	0.03	0.74	0.5	-0.24		-0.76	0.72	0.65	0.68	0.29	-0.65	0.45	0.83	0.45	0.6	0.42	0.64
Retained Earnings	-0.87	0.65	-0.56	-0.88	-0.35	-0.98	-0.86	-0.16	-0.76		-0.99	-0.88	-0.73	-0.78	0.95	-0.88	-0.97	-0.4	-0.63	-0.63	-0.94
Net Receivables	0.86	-0.63	0.59	0.84	0.27	0.96	0.85	0.17	0.72	-0.99		0.83	0.67	0.78	-0.98	0.86	0.95	0.3	0.56	0.56	0.91
Total Current Assets	0.94	-0.35	0.52	0.78	0.68	0.91	0.71	0.1	0.65	-0.88	0.83		0.65	0.82	-0.77	0.87	0.85	0.39	0.77	0.88	0.92
Short Term Debt	0.51	-0.64	0.21	0.81	0.24	0.68	0.73	0.3	0.68	-0.73	0.67	0.65		0.46	-0.57	0.5	0.66	0.56	0.5	0.34	0.61
Common Stock	0.89	-0.08	0.74	0.49	0.57	0.76	0.67	0.23	0.29	-0.78	0.78	0.82	0.46		-0.75	0.94	0.67	0.23	0.59	0.67	0.78
Net Tangible Assets	-0.85	0.61	-0.6	-0.76	-0.25	-0.95	-0.87	-0.26	-0.65	0.95	-0.98	-0.77	-0.57	-0.75		-0.86	-0.91	-0.24	-0.51	-0.52	-0.9
Capital Surpluse	0.94	-0.29	0.69	0.61	0.58	0.88	0.77	0.25	0.45	-0.88	0.86	0.87	0.5	0.94	-0.86		0.8	0.33	0.69	0.77	0.91
Long Term Debt Total	0.81	-0.7	0.45	0.91	0.26	0.95	0.76	-0.01	0.83	-0.97	0.95	0.85	0.66	0.67	-0.91	0.8		0.32	0.63	0.6	0.91
Short Long Term Debt	0.24	-0.46	0.2	0.41	0.38	0.37	0.45	0.27	0.45	-0.4	0.3	0.39	0.56	0.23	-0.24	0.33	0.32		0.31	0.41	0.43
Net Invested Capital	0.69	-0.26	0.03	0.7	0.46	0.67	0.4	-0.07	0.6	-0.63	0.56	0.77	0.5	0.59	-0.51	0.69	0.63	0.31		0.77	0.64
Net Working Capital	0.84	-0.08	0.43	0.5	0.86	0.72	0.51	0.11	0.42	-0.63	0.56	0.88	0.34	0.67	-0.52	0.77	0.6	0.41	0.77		0.79
Capital Stock	0.93	-0.52	0.62	0.76	0.57	0.97	0.88	0.28	0.64	-0.94	0.91	0.92	0.61	0.78	-0.9	0.91	0.91	0.43	0.64	0.79

Click cells to compare fundamentals

About PTC Therapeutics Financial Statements

PTC Therapeutics shareholders use historical fundamental indicators, such as Gross Profit, to determine how well the company is positioned to perform in the future. Although PTC Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in PTC Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on PTC Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Gross Profit	872.3 M	916 M
Gross Profit Margin	0.93	0.98

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for PTC Stock Analysis

When running PTC Therapeutics' price analysis, check to measure PTC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PTC Therapeutics is operating at the current time. Most of PTC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PTC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PTC Therapeutics' price. Additionally, you may evaluate how the addition of PTC Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC